CATALOGO DEI PRODOTTI DELLA RICERCA

MILELLA, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.836
NA - Nord America 5.488
AS - Asia 4.425
SA - Sud America 472
AF - Africa 102
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 16.349
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.385
SG - Singapore 2.000
CN - Cina 1.709
IT - Italia 910
GB - Regno Unito 820
RU - Federazione Russa 800
FR - Francia 776
IE - Irlanda 705
DE - Germania 577
SE - Svezia 552
BR - Brasile 415
FI - Finlandia 343
HK - Hong Kong 145
ID - Indonesia 142
KR - Corea 123
CA - Canada 83
NL - Olanda 76
UA - Ucraina 73
VN - Vietnam 63
AT - Austria 52
TG - Togo 50
IN - India 40
JP - Giappone 37
PL - Polonia 28
CZ - Repubblica Ceca 24
TH - Thailandia 24
BE - Belgio 19
IR - Iran 19
AU - Australia 17
EG - Egitto 17
TR - Turchia 17
AR - Argentina 12
PK - Pakistan 11
CH - Svizzera 10
MY - Malesia 10
UZ - Uzbekistan 10
ZA - Sudafrica 10
ES - Italia 9
MA - Marocco 9
AZ - Azerbaigian 8
CO - Colombia 8
MX - Messico 8
PE - Perù 8
BD - Bangladesh 7
EU - Europa 7
KG - Kirghizistan 7
CL - Cile 6
IQ - Iraq 6
LU - Lussemburgo 6
PY - Paraguay 6
SK - Slovacchia (Repubblica Slovacca) 6
BG - Bulgaria 5
EC - Ecuador 5
HR - Croazia 5
LT - Lituania 5
LV - Lettonia 5
RO - Romania 5
UY - Uruguay 5
VE - Venezuela 5
AM - Armenia 4
IL - Israele 4
JO - Giordania 4
KE - Kenya 4
MK - Macedonia 4
PH - Filippine 4
SA - Arabia Saudita 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
CU - Cuba 3
DK - Danimarca 3
KH - Cambogia 3
KZ - Kazakistan 3
NO - Norvegia 3
NP - Nepal 3
PS - Palestinian Territory 3
TW - Taiwan 3
CR - Costa Rica 2
DZ - Algeria 2
GR - Grecia 2
HN - Honduras 2
HU - Ungheria 2
LA - Repubblica Popolare Democratica del Laos 2
OM - Oman 2
PA - Panama 2
PT - Portogallo 2
SN - Senegal 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
CG - Congo 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
GA - Gabon 1
GS - Georgia del Sud e Isole Sandwich Australi 1
GT - Guatemala 1
KW - Kuwait 1
Totale 16.340
Salva come PNG Salva come JPEG
Città #
Chandler 1.264
Singapore 1.126
Southend 738
Dublin 682
Beijing 341
Woodbridge 333
Verona 332
Ashburn 305
Jacksonville 299
Lawrence 267
Princeton 267
Ann Arbor 197
Helsinki 187
Sindelfingen 185
Houston 171
Redmond 139
Jakarta 137
Hong Kong 135
Wilmington 135
Jinan 134
New York 107
Munich 104
Nanjing 84
Shenyang 80
Milan 79
The Dalles 72
Hebei 61
Seattle 59
Nuremberg 51
Toronto 51
Lomé 50
Tianjin 49
Ningbo 44
São Paulo 38
Changsha 37
Seoul 37
Los Angeles 36
Zhengzhou 36
Santa Clara 33
Boardman 31
Guangzhou 31
Haikou 31
Hangzhou 31
Kent 31
Amsterdam 30
Council Bluffs 30
Dallas 30
Nanchang 30
Dong Ket 29
Tokyo 29
Frankfurt am Main 27
Moscow 27
Taiyuan 27
Washington 27
Redwood City 25
Taizhou 25
Vienna 24
Rome 23
Fuzhou 22
Jiaxing 22
Bangkok 21
Andover 20
Brno 20
Lanzhou 20
Lappeenranta 20
London 20
Brussels 19
Chicago 18
Falkenstein 18
Dongguan 17
San Francisco 17
Shanghai 17
Fairfield 14
Ottawa 14
Belo Horizonte 13
Brescia 13
Cedar Knolls 12
Falls Church 12
Bologna 11
Norwalk 11
Paris 10
Tashkent 10
Cairo 9
Cambridge 9
Padova 9
Rio de Janeiro 9
Trento 9
Zanjan 9
Huskvarna 8
Lima 8
Salvador 8
Baku 7
Boydton 7
Chions 7
Clearwater 7
Este 7
Kochi 7
Laurel 7
The Hague 7
Bishkek 6
Totale 9.551
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 191
Genomic characterization of hepatoid tumors: context matters 135
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 126
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 125
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models 117
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 116
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 114
ERK 1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia 112
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 109
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen 106
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 106
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 102
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 102
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 100
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 99
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder 98
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 97
Sex differences in oncogenic mutational processes 94
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 93
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 92
Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19 92
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions 92
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer 89
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 88
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 88
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 88
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 85
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 84
Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer 84
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 83
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 83
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 83
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 82
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? 81
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 81
Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma 80
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 80
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 80
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 80
Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer 79
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 79
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 79
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 78
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 77
Do immune checkpoint inhibitors need new studies methodology? 76
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 76
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 76
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 74
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 74
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 73
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 73
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 73
The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome 72
DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association 72
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 72
Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer. 71
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 71
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 71
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 70
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 69
Cardiotoxicity and Incidence Of Brain Metastases After Adjuvant Trastuzumab for Early Breast Cancer: The Dark Side of the Moon? A Meta-Analysis of The Randomized Trials. 69
The Italian Rare Pancreatic Exocrine Cancer Initiative 69
Muscle derangement and alteration of the nutritional machinery in NSCLC 69
Autoantibody signature in human ductal pancreatic adenocarcinoma 69
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 69
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 69
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 69
Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial 69
Pan-cancer analysis of whole genomes 68
Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients 67
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. 67
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer 67
Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward 67
Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites 67
Physical activity and exercise in lung cancer care: will promises be fulfilled? 66
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 66
Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine 66
Exercise levels and preferences in cancer patients: a cross-sectional study 66
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 66
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets 66
Factors influencing physical activity in cancer patients during oncological treatments: a qualitative study 66
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma 66
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 66
A multimodal approach to cancer-related cachexia: from theory to practice 66
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 66
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 66
"Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms 66
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 65
Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar 65
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 65
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona 64
IL CARCINOMA POLMONARE A GRANDI CELLULE 63
Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer 63
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss 63
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 63
Magnitude of Benefit of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: Meta-Analysis of Randomized Clinical Trials. 62
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. 62
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 62
Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology 62
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 62
Totale 8.026
Salva come PNG Salva come JPEG
Categoria #
all - tutte 87.397
article - articoli 86.729
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 668
Totale 174.794
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020225 0 0 0 0 0 0 0 0 0 51 57 117
2020/20211.111 93 259 52 122 146 119 37 34 43 25 110 71
2021/20221.789 110 378 60 108 46 22 37 103 59 37 310 519
2022/20234.070 290 364 383 714 323 1.057 61 223 440 49 105 61
2023/20242.607 91 167 234 360 225 356 206 191 56 126 419 176
2024/20255.295 438 354 332 1.393 349 302 437 439 1.112 139 0 0
Totale 16.836